Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Plasma Genotyping Yields Actionable Mutation in Advanced NSCLC

Publish date:: April 9, 2019

Key clinical point: Next-generation sequencing of cell-free plasma DNA identifies NSCLC mutations.

Major finding: The sensitivity of NGS plasma was 75% for oncogenic driver mutations.

Study details: Prospective comparison of genotyping methods in samples from 127 patients with advanced NSCLC.

Disclosures: The study was supported by Illumina. Authors from MSKCC and MD Anderson were supported by National Institutes of Health grants. Dr. Li received consulting/advisory board fees from Genentech, Thermo-Fisher Scientific, and Guardant Health outside of the submitted work. Multiple coauthors reported similar relationships, and eight coauthors were current or former employees of Illumina.

Citation:

Li BT et al. Ann Oncol. 2019 Mar 20. doi: 10.1093/annonc/mdz046.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,